Lifestyle Asset Management Inc. Acquires 57,799 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Lifestyle Asset Management Inc. increased its holdings in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 422.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 71,488 shares of the company’s stock after buying an additional 57,799 shares during the period. Lifestyle Asset Management Inc.’s holdings in Dr. Reddy’s Laboratories were worth $1,129,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of RDY. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of Dr. Reddy’s Laboratories by 318.0% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 372,900 shares of the company’s stock worth $28,411,000 after buying an additional 283,700 shares during the last quarter. Artemis Investment Management LLP increased its stake in Dr. Reddy’s Laboratories by 398.3% in the fourth quarter. Artemis Investment Management LLP now owns 295,530 shares of the company’s stock valued at $4,666,000 after purchasing an additional 236,224 shares in the last quarter. Fisher Asset Management LLC increased its stake in Dr. Reddy’s Laboratories by 59.4% in the third quarter. Fisher Asset Management LLC now owns 491,303 shares of the company’s stock valued at $39,034,000 after purchasing an additional 183,146 shares in the last quarter. Millennium Management LLC increased its stake in Dr. Reddy’s Laboratories by 61.4% in the second quarter. Millennium Management LLC now owns 332,502 shares of the company’s stock valued at $25,333,000 after purchasing an additional 126,472 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Dr. Reddy’s Laboratories by 12.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company’s stock valued at $76,455,000 after purchasing an additional 114,294 shares in the last quarter. 3.85% of the stock is owned by institutional investors.

Dr. Reddy’s Laboratories Price Performance

RDY stock opened at $14.16 on Friday. The stock has a market cap of $11.82 billion, a PE ratio of 22.61 and a beta of 0.51. The stock has a 50-day moving average price of $14.87 and a two-hundred day moving average price of $15.53. Dr. Reddy’s Laboratories Limited has a 1 year low of $13.61 and a 1 year high of $16.89. The company has a current ratio of 1.92, a quick ratio of 1.36 and a debt-to-equity ratio of 0.02.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.81% and a return on equity of 18.53%. Equities analysts forecast that Dr. Reddy’s Laboratories Limited will post 0.81 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on RDY shares. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Nomura downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. Finally, Barclays lowered their target price on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.